Jackson Creek Investment Advisors LLC
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1831003
CASTLE ROCK, CO
Position in PTGX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$1,586
-$2,009,239 QoQ
Shares Held
11,610
-74.0% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#321
of 341 holders
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jackson Creek Investment Advisors LLC holds $9,711,003 across 17 Biotechnology names. PTGX ranks #11 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
6,037 | $1,908,235 | |
| 2 | TVTX |
Travere Therapeutics, Inc.
|
30,801 | $1,749,804 | |
| 3 | TBPH |
Theravance Biopharma, Inc.
|
85,508 | $1,453,636 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
4,740 | $1,142,197 | |
| 5 | RPRX |
Royalty Pharma plc
|
12,743 | $714,500 | |
| 6 | VCEL |
Vericel Corp
|
14,393 | $640,344 | |
| 7 | WVE |
Wave Life Sciences, Inc.
|
92,662 | $538,366 | |
| 8 | JANX |
Janux Therapeutics, Inc.
|
34,719 | $533,283 |
All Filings in PTGX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,586 | 11,610 | Shares | Sole | 2026-08-10 | |
| 2024-09-30 | $2,010,825 | 44,685 | Shares | Sole | 2024-11-04 | |
| 2024-06-30 | $1,200,657 | 34,651 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $1,004,218 | 34,712 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||